MAXCYTE, INC. Logo

MAXCYTE, INC.

Provides a scalable, non-viral electroporation platform for cell therapy development.

MXCT | US

Overview

Corporate Details

ISIN(s):
US57777K1060 (+2 more)
LEI:
54930053YHXULRFCU991
Country:
United States of America
Address:
9713 KEY WEST AVENUE,, 20850 ROCKVILLE
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

MaxCyte, Inc. is a commercial-stage cell-engineering company providing enabling platform technologies for the discovery, development, and commercialization of cell-based therapeutics. The company's core offering is its proprietary, non-viral Flow Electroporation® technology, delivered through the scalable ExPERT™ platform. This system facilitates high-efficiency engineering of complex cell types for a wide range of applications, including cell therapy, protein production, cell-based assays, and gene editing. In addition to its technology platform, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate gene editing safety. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-26 11:14
Director's Dealing
Correction: Vesting of RSUs and PDMR Dealing
English 57.0 KB
2025-03-26 08:00
Director's Dealing
Vesting of RSUs and PDMR Dealing
English 55.7 KB
2025-03-25 11:30
Major Shareholding Notification
Holding(s) in Company
English 88.0 KB
2025-03-25 11:28
Major Shareholding Notification
Holding(s) in Company
English 87.7 KB
2025-03-25 11:26
Major Shareholding Notification
Holding(s) in Company
English 87.8 KB
2025-03-25 11:22
Major Shareholding Notification
Holding(s) in Company
English 87.8 KB

Automate Your Workflow. Get a real-time feed of all MAXCYTE, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MAXCYTE, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MAXCYTE, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden
APTA
APTAMER GROUP PLC Logo
Develops custom aptamer-based binders as antibody alternatives for life science applications.
United Kingdom
APTA
Aptevo Therapeutics Inc. Logo
Developing multi-specific antibody immunotherapies for hematologic and solid tumor cancers.
United States of America
APVO
Biotech R&D using a miniature pig model, offering CRO services and biomaterials to pharma.
South Korea
149300
Aran Research & Development (1982) Ltd. Logo
End-to-end product & machine development for plastics, medical, and industrial markets.
Israel
ARAN
Artiva Biotherapeutics, Inc. Logo
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America
ARTV
ARVINAS, INC. Logo
Develops protein degradation drugs for oncology & neuroscience, targeting undruggable proteins.
United States of America
ARVN
Asarina Pharma AB Logo
Developed Sepranolone for neurological disorders like Tourette's, OCD, and menstrual migraine.
Sweden
ASAP
Atara Biotherapeutics, Inc. Logo
Pioneering off-the-shelf allogeneic T-cell immunotherapies for cancer and autoimmune diseases.
United States of America
ATRA
Bioengineering solutions to accelerate life sciences research, from gene synthesis to cell lines.
South Korea
355690

Talk to a Data Expert

Have a question? We'll get back to you promptly.